Evidence map›Paper›PMID 35892879›Full record

ArticleCancers2022

The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer.

Christopher B Nahm, John Turchini, Sumit Sahni, Elizabeth Moon, Malinda Itchins, Jennifer Arena, Angela Chou, Emily K Colvin, Viive M Howell, Nick Pavlakis and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Christopher B NahmThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.ORCID 0000-0003-0888-4499
John TurchiniThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.
Sumit SahniThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.ORCID 0000-0002-2900-8845
Elizabeth MoonThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.
Malinda ItchinsThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.
Jennifer ArenaAustralian Pancreatic Centre, Sydney, NSW 2565, Australia.
Angela ChouThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.ORCID 0000-0001-9212-6927
Emily K ColvinThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.
Viive M HowellThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.ORCID 0000-0002-2356-3231
Nick PavlakisThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.ORCID 0000-0002-1738-0316
Stephen ClarkeThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.
Jaswinder S SamraThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.
Anthony J GillThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.
Anubhav MittalThe University of Sydney, Northern Clinical School, Faculty of Medicine and Health Sciences, Sydney, NSW 2565, Australia.ORCID 0000-0003-3960-2968
The University of Sydney · AURoyal North Shore Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The genomic heterogeneity of pancreatic ductal adenocarcinoma (PDAC) is becoming increasingly appreciated. We aimed to evaluate the ability of a triple biomarker panel (S100A4, Ca-125, and mesothelin) to predict: (i) genetic PDAC subtypes; (ii) clinical phenotypes; and (iii) the optimal treatment strategy (neoadjuvant vs. surgery-first) in resectable and borderline resectable PDAC. Patients who underwent resection for resectable and borderline resectable PDAC were included from one single-institutional cohort and one multi-institutional cohort from the Australian Pancreatic Genome Initiative (APGI). Tumors were immunohistochemically evaluated for S100A4, Ca-125, and mesothelin, and a subset from the APGI cohort underwent RNA sequencing. This study included 252 and 226 patients from the single institution and the APGI cohorts, respectively. Triple-negative biomarker status correlated with non-squamous PDAC genotypes (

Indexed as

biomarkerneoadjuvant chemotherapypancreatic cancerresectionselection

Identifiers

PMID35892879
PMCPMC9367299
OpenAlexW4287832301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.